|
|
|
|
|
|
Sponsors and Collaborators: |
University of Oxford British Heart Foundation Bayer Solvay Pharmaceuticals |
Information provided by: | University of Oxford |
ClinicalTrials.gov Identifier: | NCT00135226 |
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents “serious vascular events” (i.e. non-fatal heart attack, non-fatal stroke or death from vascular causes) in patients with diabetes who are not known to have occlusive arterial disease and to assess the effects on serious bleeding or other adverse events.
Condition | Intervention | Phase |
Diabetes Mellitus |
Drug: aspirin Drug: Omega-3-acid Ethyl Esters |
Phase IV |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Omacor Acetylsalicylic acid |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes |
Estimated Enrollment: | 10000 |
Study Start Date: | March 2005 |
The role of antiplatelet therapy (chiefly aspirin) for the secondary prevention of heart attacks and strokes is firmly established for many high-risk people with diagnosed arterial disease, and the proportional reductions in these cardiovascular events appear to be about one quarter, whether or not such patients have diabetes. But, most younger and middle-aged people with diabetes do not have manifest arterial disease - although they are still at significant cardiovascular risk - and yet few trials have tested aspirin in such individuals. As a result, there is substantial uncertainty about the role of aspirin for the prevention of heart attacks and strokes among apparently healthy people with diabetes, and only a small minority receives it.
There is consistent evidence from observational studies of lower rates of cardiovascular disease (particularly cardiac and sudden death) in people with higher intakes, or higher blood levels, of fish oils (omega-3 fatty acids). Trials in people who have survived a heart attack have shown modest, but potentially worthwhile, reductions in coronary events. There have been, however, no large-scale trials of the use of fish oils for the prevention of vascular events in people without diagnosed arterial disease.
If ASCEND can reliably demonstrate that aspirin and/or fish oils safely reduce the risk of cardiovascular events and deaths in people with diabetes who do not have pre-existing arterial disease, then this would be relevant to some tens of millions of people world-wide (who are currently not receiving such therapy) and might save tens of thousands of lives each year.
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jill Barton | 44 1865 743814 | jill.barton@ctsu.ox.ac.uk |
Contact: Louise J Bowman, BA, MBBS, MRCP | 441865 743875 | louise.bowman@ctsu.ox.ac.uk |
United Kingdom | |||||
Clinical Trial Service Unit, University of Oxford | Recruiting | ||||
Oxford, United Kingdom, OX3 7LF | |||||
Contact: Jane M Armitage, BM BChBSc, MBBS, MRCP, FFPH 44 1865 743810 jane.armitage@ctsu.ox.ac.uk |
University of Oxford |
British Heart Foundation |
Bayer |
Solvay Pharmaceuticals |
Principal Investigator: | Jane M Armitage, BSc, MBBS, MRCP, FFPH | Clinical Trial Service Unit, University of Oxford |
Click here for more information about ASCEND : A Study of Cardiovascular Events iN Diabetes 
  |
Study ID Numbers: | CTSUASCEND1, EUDRACT: 2004-000991-15 |
First Received: | August 24, 2005 |
Last Updated: | January 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00135226 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
|
|